10 Small-Cap Stocks With Huge Growth Potential

5. Nuvation Bio Inc. (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small-cap stocks with huge growth potential. Nuvation Bio Inc. (NYSE:NUVB) announced on February 9 the finalization of a protocol amendment to the ongoing global SIGMA study of safusidenib that expands it to a Phase 3 trial. Safusidenib is a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, and SIGMA is involved in the evaluation of the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma following standard-of-care.

Nuvation Bio Inc. (NYSE:NUVB) stated that the new protocol expands patient eligibility in the registrational portion of the trial and includes those with grades 2 and 3 IDH1-mutant astrocytoma with high-risk features and grade 4 IDH1-mutant astrocytoma, after standard-of-care radiation or chemoradiation and adjuvant temozolomide.

In a separate development, Truist lifted the price target on Nuvation Bio Inc. (NYSE:NUVB) to $13 from $11 on January 27, maintaining a Buy rating on the shares. The update came as part of a broader research note previewing fiscal Q4 earnings in biotech. The firm stated that it believes the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake positioning Ibtrozi as the ROS1 agent of choice versus competitors despite seasonal headwinds.

Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology. It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC).